公开(公告)号：US20190194732A1

公开(公告)日：2019-06-27

申请号：US16321150

申请日：2017-07-28

申请人： Ginkgo Bioworks, Inc.

发明人： Joseph Jacobson

IPC分类号： C12Q1/6834 ,  C07H21/04 ,  B01J19/00 ,  C07H21/02

CPC分类号： C12Q1/6834 ,  B01J19/00 ,  B01J2219/005 ,  B01J2219/00545 ,  B01J2219/00547 ,  B01J2219/00576 ,  B01J2219/00585 ,  B01J2219/00722 ,  C07H1/00 ,  C07H21/00 ,  C07H21/02 ,  C07H21/04 ,  C12Q2537/143 ,  C12Q2563/107 ,  C12Q2563/149

摘要： Devices and methods are provided for multiplex nucleic acid assembly. Specifically, the device includes a plurality of differentially labeled particles or beads, such that when in use, the labeled particles can barcode different oligonucleotides. The device can be used for nucleic acid singulation during and/or after assembly.

公开(公告)号：US20190185538A1

公开(公告)日：2019-06-20

申请号：US16227601

申请日：2018-12-20

申请人： BRISTOL-MYERS SQUIBB COMPANY

发明人： Robert James Peach ,  Joseph Naemura ,  Peter S. Linsley ,  Jurgen Bajorath

IPC分类号： C07K14/725 ,  C07K14/705 ,  A61K38/17 ,  A61K39/39 ,  C07H21/04 ,  C12N5/0783 ,  A61K39/395

CPC分类号： C07K14/7051 ,  A61K38/00 ,  A61K38/1774 ,  A61K39/39 ,  A61K39/3955 ,  A61K2039/505 ,  C07H21/04 ,  C07K14/70521 ,  C07K2319/30 ,  C12N5/0636 ,  C12N2501/51

摘要： The present invention provides soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig. The soluble CTLA4 molecules have a first amino acid sequence comprising the extracellular domain of CTLA4, where certain amino acid residues within the S25-R33 region and M97-G107 region are mutated. The mutant molecules of the invention may also include a second amino acid sequence which increases the solubility of the mutant molecule.

公开(公告)号：US20190032050A1

公开(公告)日：2019-01-31

申请号：US15556946

申请日：2016-03-09

申请人： Daxiang Cui ,  Chunlei Zhang ,  UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION

发明人： Peixuan Guo ,  Daxiang Cui ,  Dan Shu ,  Yi Shu ,  Chunlei Zhang

IPC分类号： C12N15/113 ,  C12N15/115 ,  A61P35/00

CPC分类号： C12N15/113 ,  A61P35/00 ,  C07H21/04 ,  C12N15/111 ,  C12N15/115 ,  C12N2310/14 ,  C12N2310/16 ,  C12N2310/3519 ,  C12N2310/52 ,  C12N2320/32

摘要： The presently-disclosed subject matter relates to RNA-based composition and method to treat gastric cancer in a subject. More particularly, the presently disclosed subject matter relates to a RNA nanostructure and composition containing a multiple branched RNA nanoparticle, a gastric cancer targeting module, and an effective amount of a therapeutic agent. Further, the presently disclosed subject matter relates to a method of using the RNA nanoparticle composition to treat gastric cancer in a subject having or at risk of having gastric cancer.

公开(公告)号：US20180327850A1

公开(公告)日：2018-11-15

申请号：US15739480

申请日：2016-06-20

申请人： Proteovista LLC

发明人： Mary Szatkowski Ozers ,  Christopher L. Warren ,  Matthew J. Rodesch

IPC分类号： C12Q1/6886 ,  C40B60/12

CPC分类号： C12Q1/6886 ,  C07H21/02 ,  C07H21/04 ,  C12Q1/6883 ,  C12Q2600/156 ,  C40B60/12

摘要： Provided herein is technology relating to genetic determinants of disease and particularly, but not exclusively, to methods, compositions, and systems for identifying single nucleotide polymorphisms that are functionally associated with a disease.

公开(公告)号：US20180273578A1

公开(公告)日：2018-09-27

申请号：US15925887

申请日：2018-03-20

申请人： Boehringer Ingelheim International GmbH

发明人： Thorsten OOST ,  Martin FLECK ,  Christian Andreas KUTTRUFF ,  Sebastian CAROTTA

IPC分类号： C07H21/04 ,  A61K31/7084 ,  A61K39/39

CPC分类号： C07H21/04 ,  A61K31/7084 ,  A61K39/39 ,  A61K45/06 ,  A61K2039/55511 ,  C07H21/02

摘要： Compounds of formula (I) wherein Base1 and Base2 are defined as in claim 1 are modulators of STING.

公开(公告)号：US10080354B2

公开(公告)日：2018-09-25

申请号：US14426482

申请日：2013-09-06

申请人： Children's Medical Center Corporation

发明人： Derrick J. Rossi ,  Roi Gazit

IPC分类号： A01K67/027 ,  A61K48/00 ,  C07H21/04 ,  C12Q1/6897 ,  G01N33/50

CPC分类号： A01K67/0278 ,  A01K67/0275 ,  A01K2217/072 ,  A01K2227/105 ,  A01K2267/02 ,  C07H21/04 ,  C12N2517/02 ,  C12Q1/6897 ,  G01N33/5073

摘要： Described herein are nucleic acid constructs, hematopoietic stem cell identifier animals, and methods of using thereof for isolating hematopoietic stem cell populations. Also provided are methods of using the identifier animals and cells isolated from them to screen for agents that affect the growth, proliferation, potency, expansion, or maintenance of the stem cells. Such agents can be used for promoting growth of stem cells in vitro or in vivo, and also for inhibiting cancer cells that have been determined to resemble a stem cell.

公开(公告)号：US10077441B2

公开(公告)日：2018-09-18

申请号：US15110712

申请日：2015-01-09

申请人： Helge Zieler

发明人： Helge Zieler

IPC分类号： C12N15/74 ,  C12P21/04 ,  C12P21/06 ,  C07H21/04 ,  C12N15/10

CPC分类号： C12N15/1079 ,  C07H21/04 ,  C07K2319/00 ,  C12N15/10 ,  C12N15/74

摘要： The present invention relates to compositions involving randomized in-frame fusion polynucleotides and their introduction into a host organism to identify desirable phenotypic changes. The present invention further relates to methods of generating these randomized in-frame fusion polynucleotides by introducing randomized in-frame fusion polynucleotides into an organism, selecting for organisms with new or altered phenotypes, re-isolating the randomized in-frame fusion polynucleotides from the selected organisms, re-assembling the constituent polynucleotides of the re-isolated randomized in-frame fusion polynucleotides into new collections of randomized in-frame fusion polynucleotides, and repeating the selection for organisms with new or altered phenotypes.

公开(公告)号：US20180258132A1

公开(公告)日：2018-09-13

申请号：US15979729

申请日：2018-05-15

申请人： GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED

发明人： Jerry ADAMS ,  Yiqian LIAN

IPC分类号： C07H21/04 ,  C07H21/02 ,  C07F9/6574 ,  A61K31/7084 ,  A61K39/39 ,  A61K39/00

CPC分类号： C07H21/04 ,  A61K31/7084 ,  A61K39/39 ,  A61K2039/55511 ,  C07F9/65746 ,  C07H21/00 ,  C07H21/02

摘要： A compound of Formula (I) wherein Y1, Y2, X1, X2, R1, R2, R3, R4, R5, R6, R8, and R9 are as defined herein; and pharmaceutically acceptable salts and tautomers thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, in the treatment of diseases in which modulation of STING (Stimulator of Interferon Genes) is beneficial, for example inflammation, allergic and autoimmune diseases, infectious diseases, cancer, pre-cancerous syndromes and as vaccine adjuvants.

公开(公告)号：US20180245141A1

公开(公告)日：2018-08-30

申请号：US15694712

申请日：2017-09-01

申请人： Eidgenoessische Technische Hochschule Zurich

发明人： Dario Neri ,  Samu Melkko

IPC分类号： C12Q1/6837 ,  C07H21/00

CPC分类号： C12Q1/6837 ,  C07H21/00 ,  C07H21/02 ,  C07H21/04 ,  C12N15/1068 ,  C12Q1/6813 ,  C40B30/04 ,  C40B40/06 ,  G01N33/58 ,  C12Q2565/501 ,  C12Q2565/101 ,  C12Q2563/179

摘要： The invention concerns a chemical compound comprising a chemical moiety (p) capable of performing a binding interaction with a target molecule (e.g. a biological target) and further comprising an oligonucleotide (b) or functional analogue thereof. In a first embodiment according to the invention, the chemical compound is characterized in that the oligonucleotide (b) or functional analogue comprises at least one self-assembly sequence (b1) capable of performing a combination reaction with at least one self-assembly sequence (b1′) of a complementary oligonucleotide or functional analogue bound to another chemical compound comprising a chemical moiety (q). In a second embodiment according to the invention, the chemical compound which comprises a coding sequence (b1) coding for the identification of the chemical moiety (p) is characterized in that the chemical compound further comprises at least one self-assembly moiety (m) capable of performing a combination reaction with at least one self-assembly moiety (m′) of a similar chemical compound comprising a chemical moiety (q). The invention comprises corresponding libraries of chemical compounds as well as methods of biopanning of target molecules and of identifying such targets.

公开(公告)号：US20180237778A1

公开(公告)日：2018-08-23

申请号：US15863667

申请日：2018-01-05

申请人： Roche Innovation Center Copenhagen A/S

发明人： Signe M. Christensen ,  Nikolaj Dam Mikkelsen ,  Miriam Frieden ,  Henrik Frydenlund Hansen ,  Troels Koch ,  Daniel Sejer Pedersen ,  Christoph Rosenbohm ,  Charlotte Albaek Thrue ,  Majken Westergaard

IPC分类号： C12N15/113 ,  C07H19/04 ,  C07H19/06 ,  C07H19/16 ,  C07H21/00 ,  C07H21/02 ,  C07H21/04 ,  A61K31/7088 ,  C12N15/11

CPC分类号： C12N15/113 ,  A61K31/7088 ,  C07H19/04 ,  C07H19/06 ,  C07H19/16 ,  C07H21/00 ,  C07H21/02 ,  C07H21/04 ,  C12N15/111 ,  C12N15/1137 ,  C12N2310/11 ,  C12N2310/315 ,  C12N2310/3231 ,  C12N2310/341 ,  C12N2310/344 ,  C12N2320/30 ,  C12N2320/51

摘要： A novel class of pharmaceuticals which comprises a Locked Nucleic Acid (LNA) which can be used in antisense therapy. These novel oligonucleotides have improved antisense properties. The novel oligonucleotides are composed of at least one LNA selected from beta-D-thio/amino-LNA or alpha-L-oxy/thio/amino-LNA. The oligonucleotides comprising LNA may also include DNA and/or RNA nucleotides.